Key result
A DDDRP pacemaker with atrial antitachycardia pacing was safe (88% complication-free survival at 3 months) and successfully terminated 53% of treated atrial tachyarrhythmia episodes.
Why the study?
Does an investigational DDDRP pacemaker with atrial ATP and preventive pacing algorithms safely terminate and prevent atrial tachyarrhythmias in patients requiring permanent pacing?
Population
325 patients with conventional indications for permanent pacing, multinational.
Comparison
Investigational DDDRP pacemaker with atrial… vs Before activation of preventive pacing
Design
Cohort
Follow-up
mean 2.3+/-1.3 months
Authors
Loading...
Supports short-term safety and 53% episode termination with atrial ATP; leaves open preventive efficacy and clinical benefit pending randomized data.
Observational (n=325)
Yes
Does an investigational DDDRP pacemaker with atrial ATP and preventive pacing algorithms safely terminate and prevent atrial tachyarrhythmias in patients requiring permanent pacing?
A novel DDDRP pacemaker with atrial ATP safely terminated 53% of atrial tachyarrhythmia episodes, though its preventive pacing algorithms did not significantly reduce AT/AF burden.
Israel et al. (2001) conducted an observational in Bradycardia requiring permanent pacing with atrial tachyarrhythmias (n=325). DDDRP pacemaker (Medtronic AT500) with atrial antitachycardia pacing was evaluated on Safety of overall device functioning and efficacy in terminating spontaneous AT. A DDDRP pacemaker with atrial antitachycardia pacing was safe (88% complication-free survival at 3 months) and successfully terminated 53% of treated atrial tachyarrhythmia episodes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: